Clinical research on the treatment of advanced prostate cancer with modified Fuzheng Huayu Formula combined with endocrine therapy
扶正化瘀方加味联合内分泌疗法治疗晚期前列腺癌临床研究

摘要

目的 研究应用扶正化瘀方加味与内分泌疗法联合方案治疗晚期前列腺癌的临床疗效。方法 选取70例2023年4月-2024年3月在我院接受治疗的晚期前列腺癌患者，按照患者入院先后顺序将70例患者平均分成两组，即对照组35例与观察组35例，两组均接受内分泌疗法，同时观察组添加扶正化瘀方加味治疗。研究对比两组治疗方案的最终疗效。结果 治疗后观察组患者的血清前列腺特异抗原水平、游离前列腺特异性抗原、血管内皮生长因子低于对照组，且发生的用药不良反应少于对照组，最终取得的疾病控制有效率高于对照组，（P＜0.05）。结论 晚期前列腺癌采取内分泌疗法同时加入扶正化瘀方加味治疗，可快速改善临床指标，提升疾病控制效果。

Abstract

Objective To study the clinical efficacy of the combined treatment of modified Fuzheng Huayu Formula and endocrine therapy for advanced prostate cancer.
Methods A total of 70 patients with advanced prostate cancer who were treated in our hospital from April 2023 to March 2024 were selected. The 70 patients were evenly divided into two groups according to the order of admission, namely the control group (35 cases) and the observation group (35 cases). Both groups received endocrine therapy, and the observation group was treated with modified Fuzheng Huayu Formula. The final therapeutic effects of the two groups of treatment plans were studied and compared.
Results After treatment, the levels of serum prostate-specific antigen, free prostate-specific antigen, and vascular endothelial growth factor in the observation group were lower than those in the control group, and the incidence of adverse drug reactions was less than that in the control group. The final disease control effectiveness rate was higher than that in the control group, (P < 0.05).
Conclusion   For advanced prostate cancer, the treatment of endocrine therapy combined with the modified Fuzheng Huayu Formula can rapidly improve clinical indicators and enhance the disease control effect.